Stay updated on Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the study data related to the efficacy of pembrolizumab versus docetaxel in participants with non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) positive tumors who have experienced disease progression after platinum-containing systemic therapy.
    Difference
    0.1%
    Check dated 2024-06-06T14:41:33.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying that Chinese participants must be born, raised, and reside in China, among other health and treatment-related conditions. Previously, this section only indicated that no information was provided.
    Difference
    43%
    Check dated 2024-05-22T21:29:19.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:15:35.000Z thumbnail image

Stay in the know with updates to Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial page.